ABBV-319

Phase 1Small molecule

AbbVie

ABBV-319 is one of 72 small molecule programs targeting Dry Eye Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry Eye SyndromeRecruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Dry Eye SyndromePhase 1

Recruiting

Diffuse Large B-Cell LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

109 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

38 2

Rituxan

Oncovin

33 4

Polivy

Roche

Phase 3

20 5

Gemzar

Johnson & Johnson

Phase 3

18 6

Adriamycin

Pfizer

Phase 3

18 7

Gazyva

Roche

Phase 3

18 8

Oncovin

Eli Lilly

Phase 3

18 9

Cytoxan

BBaxter Healthcare Corporation

Rayos

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT05512390

Q1 2029

Phase 1Recruiting

Dry Eye Syndrome

NCT06977724

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT05512390·39 enrolled

Dry Eye Syndrome1 trial

A Phase1b, Multiple Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Safety, and Efficacy of ABBV-319 in Subjects With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT06977724·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ABBV-319. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-319 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-319. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

ABBV-319

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2029

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

Dry Eye Syndrome1 trial

References

Drug Info

Quick Facts

Related News